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Mixed Genotype Hepatitis C Infections and Implications for Treatment
To the Editor:
The recently licensed direct-acting antivirals (DAAs) boceprevir
and telaprevir used to treat hepatitis C virus (HCV) infection act
in a genotype-specific manner. The potential outcome of DAA
treatment regimes on mixed HCV infections, consisting of concur-
rent infection with more than one HCV genotype, has not been
considered. Standard genotyping methods are only capable of iden-
tifying the dominant genotype present within a mixed infection
sample, leaving minor genotypes undetected. We propose that
DAA treatment of mixed infections may be associated with the
occurrence of genotype switching, whereby a previously undetected
minority variant drug-resistant genotype expands to replace the
successfully treated majority variant genotype. Such genotype
switching could in some cases result in nonresponse to DAA treat-
ment and could also be incorrectly interpreted as reinfection if
genotyping is not repeated following treatment failure. As a matter
of urgency, there is a need to assess the prevalence and clinical
impact of mixed HCV infections.
To determine the prevalence of mixed HCV infections in a
cohort of patients infected with genotype (gt) 3a (n5 47) or 1a
(n5 48), we designed gt1a- and gt3a-specific primers providing
partial coverage of the envelope genes E1 and E2 of HCV. Nested
reverse transcription (RT) polymerase chain reaction (PCR)
reactions were performed using gt1a primers with gt3a-infected
samples and vice versa. Amplicons were sequenced and used to
construct maximum likelihood phylogenetic trees using the MEGA
5.0 software package to confirm genotype.
The sensitivity of the RT-PCR reactions, as determined by 90%
detection limits calculated from serial endpoint dilution RT-PCR
and probit analysis, was nine copies/reaction. Of the gt3a-infected
patient samples, 10.6% (5/47) harbored minority variant gt1a
strains, whereas none of the gt1a-infected patient samples con-
tained gt3a as a minority strain.
These findings are in keeping with other studies that found
mixed HCV infections at rates of 5%-25.3%.1-3 Further work is
required to assess the impact of minority variant strains on patients
treated with DAA therapy. If relapse following dual therapy for gt3
infection is associated with emerging dominance of preexisting gt1
strains, screening of baseline patient samples using genotype-specific
methods could result in improved treatment strategies; for example,
the prescription of triple rather than dual antiviral therapy. More
work is required to assess the impact of multiple genotype infection
on clinical outcome, and this work is more pressing in the DAA era.
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Unusual Oral Mucosa Damage During Telaprevir Treatment of Chronic Hepatitis C
To the Editor:
The addition of hepatitis C virus (HCV) protease inhibitor telap-
revir to pegylated interferon (Peg-IFN) and ribavirin (RBV) dramati-
cally increases the likelihood of a sustained virological response
(SVR) in patients with genotype 1 HCV infection who have failed
previous treatment with Peg-IFN/RBV combination.1 The higher
prevalence of cutaneous adverse reactions (CAR) of different severity
was associated with the telaprevir combination treatment, in contrast
to the treatment with Peg-IFN/RBV2; however, we could not find
any published article about isolated mucosal lesions associated with
the telaprevir combination treatment before this case.
A 29-year-old white male patient was referred to our department
in May 2012 for reevaluation and retreatment after unsuccessful treat-
ment for chronic HCV infection (genotype 1b). Previous treatment
(PegIFN-a2b 120 lg/week plus RBV 1,200 mg/day) had achieved
neither rapid nor early virological responses and was stopped after
week 13 of treatment due to a low chance of SVR. The overall toler-
ability of this treatment was satisfactory. During the treatment hemo-
globin decreased to 97 g/L, absolute neutrophil and platelet counts
decreased but not below the alarm level, and no dermatological
adverse events were noted. Due to advanced fibrosis and null-response
to the previous treatment with Peg-IFN/RBV, the patient was enrolled
in the telaprevir early access program. Triple therapy with PegIFN-a2a
180 lg subcutaneously once a week, RBV 600 mg twice daily and
telaprevir 750 mg three times a day was started. Overall tolerability of
the therapy was satisfactory. A rapid virological response was achieved
(PCR HCV RNA was negative on the fourth week of treatment). No
clinically significant hematological adverse events were noted.
At week 6 of treatment the patient complained of a tickle in his
throat, but there were no skin lesions, flu-like symptoms, or fever.
On the scheduled visit (week 8), vital signs were normal: weight
76.8 kg, temperature 36.8C, blood pressure 120/70 mmHg, heart-
beat 88/min. Mild hyperemia of oral mucosa plus multiple telan-
giectasias and erythematous lesions located on the buccal mucosa,
soft palate, and back wall of the throat were found (Fig. 1A,B). Skin
was normal, no regional lymph nodes were enlarged, no signs of
infection were found, and the patient did not note any unusual taste
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